Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (82)	12/29/1999 2:11:00 PM
From: Carl R.	Respond to of 207

I have never tried QGLY's product, but used the pure form of zinc. I agree with you that if the benefits are equivalent, QGLY will do better as lozenges should have more consumer acceptance. Given that the actual viruses grow in the nose, however, it seems plausible, and even likely, that administering doses directly to the nose could be more effective. Thus the claim that Zicam reduces the duration of the cold to 1.5 days as compared to the lozenge which claim to reduce the duration to 4.4 days is plausible. If the nasal application is highly effective, and is significantly more effective than other alternatives, I believe that the product will overcome the method of usage. If it couldn't, no one would buy suppositories, either. <VBG> I also agree with two other points in your post. First of all, I agree that ultimately the performance of the company will determine the stock price, and that all the hype won't matter in the long run. I also agree that the stock performance of QGLY is relevant, and that the QGLY performance is a strong limiting factor for GUMM. If QGLY hadn't preceded it, GUMM could well have gone to 100, but due to QGLY expectations have been tempered. The fact that QGLY initially had good sales, but that they have since fallen significantly is a good cause to question this whole area. The other big question mark, besides the ability of GUMM to actually sell the product is of course the patent suit brought by QGLY. I will probably continue to hold my small position in GUMM for a few months and see how sales go for the next quarter or two. Good luck, and thanks for the dialog, Carl